Minakem Header W48

Minakem Header W48

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

Boehringer Ingelheim GmbH

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Boehringer Ingelheim Gets Positive CHMP Opinion for Use of Pradaxa® to Treat venous thromboembolic events in Newsborns and Adults

Details:

Positive opinion is based on a dedicated clinical pediatric program for dabigatran, including the DIVERSITY study,2 which supplements dabigatran's established and well-documented safety and efficacy profile in adults

Lead Product(s): Dabigatran Etexilate Mesylate

Therapeutic Area: Cardiology/Vascular Diseases Product Name: Pradaxa

Highest Development Status: Phase II/ Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 16, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY